| Ytd | 136.59% | |
| 1y | 80.44% |
| Open | 47.98 | Prev Close | 47.98 | Low | 47.98 | High | 47.98 | Mkt Cap | 1.23B |
| Vol | 783.73K | Avg Vol | 653.27K | EPS | -3.43 | P/E | N/A | Forward P/E | -13.18 |
| Beta | 2.27 | Short Ratio | 1.12 | Inst. Own | 89.13% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | N/A | 50-d Avg | 42.23 | 200-d Avg | 23.14 | 1yr Est | 48.00 |
TRML News
Basel, October 28, 2025 - Novartis today announced that it has successfully completed its acquisitio
Basel, October 28 2025 - Novartis today announced that its previously announced tender offer (the “o
Basel, October 22, 2025 - Novartis today announced the expiration of the waiting period under the Ha
NEW YORK CITY & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti,
Basel, September 29, 2025 - Novartis today announced that Torino Merger Sub Inc., a Delaware corpora
NEW YORK , Sept. 15, 2025 /PRNewswire/ -- Class Action Attorney Juan Monteverde with Monteverde & A
NEW YORK CITY & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti,
Novartis is set to acquire Tourmaline Bio for $1.4B, adding late-stage anti-IL-6 candidate pacibekit
Tourmaline Bio (TRML) shares have had a strong run this year. News that Swiss pharma giant Novartis
Nebius surges 49% pre-market after securing a $17.4B AI infrastructure deal with Microsoft, potentia
NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether t
Novartis AG (ADR) (NYSE:NVS) has agreed to buy Tourmaline Bio in a $1.4 billion cash deal, strengthe
MILWAUKEE--(BUSINESS WIRE)--The Ademi Firm is investigating Tourmaline (NASDAQ: TRML) for possible b
Switzerland's Novartis will acquire Tourmaline Bio with an offer price of $48 per share, in a deal v
– Novartis to acquire Tourmaline Bio for $48.00 per share in cash for a total equity value of approx
Tourmaline Bio is a clinical-stage biopharmaceutical company developing pacibekitug, an anti-IL-6 mA
– Poster presentation highlights the consistency of reductions in high-sensitivity C-reactive protei
The consensus price target hints at a 151% upside potential for Tourmaline Bio, Inc. (TRML). While e
– Reported positive topline results from the ongoing Phase 2 TRANQUILITY trial of pacibekitug in May
Shares of FactSet Research Systems Inc. (NYSE: FDS) fell sharply during Thursday’s session after th
U.S. stock futures were higher this morning, with the Dow futures gaining by around 100 points on Th